The broader implication of this finding is that a HMG-CoA reductase inhibitor such as atorvastatin deserves further consideration in MYC-overexpressing tumor types, and indeed atorvastatin did have anti-tumorigenic activity in the aforementioned models of MYC-driven liver cancer and lymphoma (Shachaf et al., 2007; Cao et al., 2011). Here, HMGCR is linked to liver cancer.